(208 days)
Not Found
No
The device description and performance studies focus on a lateral flow immunoassay for detecting HCG, which is a chemical reaction-based test. There is no mention of image processing, AI, ML, or any computational analysis of the results. The interpretation is based on visual lines appearing on the test strip.
No
This device is an in-vitro diagnostic test used to detect pregnancy, not to treat or cure a disease or condition.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that both the Home and Professional versions of the David Pregnancy Test Cassette are "in-vitro diagnostic test[s] for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy." The term "in-vitro diagnostic test" directly indicates its nature as a diagnostic device.
No
The device description clearly states it is a "Cassette kit" consisting of a "test device, a disposable plastic dropper, and a package insert," and describes the physical components of the test strip. This indicates it is a physical in-vitro diagnostic device, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
- "David Home Pregnancy Test Cassette is an in-vitro diagnostic test..."
- "David Professional Pregnancy Test Cassette is an in-vitro diagnostic test..."
This clearly identifies the device as an in-vitro diagnostic product.
N/A
Intended Use / Indications for Use
David Home Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for the Over-the-Counter Use only.
David Professional Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for prescription use only.
Product codes (comma separated list FDA assigned to the subject device)
LCX, JHI
Device Description
David Pregnancy Test Cassette will be designed in one format: Cassette. The Cassette kit consists of one test device, a disposable plastic dropper, and a package insert. Each test strip contains mouse monoclonal anti-a-hCG antibody coated membrane and a pad containing mouse monoclonal anti-ß-hCG antibody colloidal gold conjugate. The control antibodies are goat anti-mouse IgG polyclonal antibody.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Home/Over-the-Counter Use (David Home Pregnancy Test Cassette)
Professional Use (David Professional Pregnancy Test Cassette)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Precision/Reproducibility Study:
Sample size: Not explicitly stated as a single number for the entire study, but involves sets of 150 samples per concentration per lot (3 lots, 7 concentrations).
Data source: Urine samples spiked with hCG at various concentrations (0, 16, 18.75, 20, 25, 27.5 and 100mIU/mL).
Annotation protocol: Not explicitly detailed as an annotation protocol, rather the results are reported as Positive/Negative counts out of 150 for each concentration and lot.
Detection Limit Study:
Sample size: Each concentration detected 90 times totally in each test site; 60 times by professionals (30 times with professional kit, 30 times with home use kit), and 30 times by lay users.
Data source: Urine samples spiked with hCG at various concentrations (0, 12.5, 16, 18.75, 20, 22.5, 25, 27.5, 50 and 100mIU/mL).
Annotation protocol: Results presented as Positive counts out of 90, and Positive Ratio. Not explicitly detailed as an annotation protocol.
Cross-reactivity Study:
Sample size: 20 fresh urine specimens (10 healthy non-pregnant women and 10 healthy men) for each homogenous hormone.
Data source: Urine specimens spiked with LH, FSH, and TSH; negative (0 mIU/mL) and positive (25mIU/ml) hCG samples were used.
Annotation protocol: Results presented as Positive/Negative counts (e.g., -/- (20/20), +/+ (20/20)). Not explicitly detailed as an annotation protocol.
Interference Study:
Sample size: Three devices of each format were tested for each substance.
Data source: Negative and positive hCG urine samples (25 mIU/mL) individually spiked with various interfering substances.
Annotation protocol: Not explicitly detailed as an annotation protocol, but claims "No interference was observed."
Effects of urine pH Study:
Sample size: Not explicitly stated.
Data source: Negative and positive hCG urine samples (25 mIU/mL) tested across a pH range of 3-10.
Annotation protocol: Not explicitly detailed as an annotation protocol, but claims "pH ranging from 3 to 10 in urine samples does not interfere with the performance of the test."
Specific Gravity Study:
Sample size: Not explicitly stated.
Data source: Negative urine and positive urine with specific gravity from 1.000 to 1.050.
Annotation protocol: Not explicitly detailed as an annotation protocol, but claims "specific gravity ranging from 1.000 to 1.050in urine samples does not interfere with the performance of the test."
High dose hook effect study:
Sample size: Not explicitly stated.
Data source: Negative urine specimens spiked with high hCG concentrations ranging from 50 mIU/mL to 2,000,000 mIU/mL.
Annotation protocol: Not explicitly detailed as an annotation protocol, but claims "All samples yielded the expected positive results."
Effects of hCG ß-core fragment study:
Sample size: Samples of each concentration were tested 10 times with the professional and lay-user respectively.
Data source: Negative urine hCG (0 mIU/mL, 16mIU/mL HCG) and positive urine samples (27.5 mIU/mL hCG) spiked with hCG beta core fragment standard at several different concentrations up to 1,000,000 pmol/L.
Annotation protocol: Not explicitly detailed as an annotation protocol, but results demonstrated "no hook effect was observed at an hCG ß-core fragment concentration up to 100,000 pmol/L."
Method comparison with predicate device:
Sample size: 360 fresh women urine samples.
Data source: Fresh women urine samples.
Annotation protocol: Test results by the predicate device and candidate device by professionals were compared for agreement.
Lay-user study:
Sample size: 120 female volunteers aged from 18-45 (40 from each of three sites).
Data source: Volunteers' own urine samples, and 3 other samples spiked with HCG (27.5 mIU/mL, 20 mIU/mL, and an unspecified third concentration). Volunteers also answered a questionnaire.
Annotation protocol: Volunteers conducted the test according to instructions for use. Test results were recorded. For the questionnaire, responses were recorded on a Likert scale (1 to 5). Readability of labels was assessed using Flesch-Kincaid software.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study Type: Analytical Performance (Precision/Reproducibility, Traceability, Stability, Detection Limit, Analytical Specificity/Cross-reactivity, Interference, Effects of urine pH, Specific Gravity, High dose hook effect, Effects of hCG ß-core fragment) and Comparison Study (Method comparison with predicate device, Lay-user study).
Sample Size:
- Precision/Reproducibility: Samples with hCG spiked at concentrations of 0, 16, 18.75, 20, 25, 27.5 and 100mIU/mL in urine, tested 150 times per concentration per lot across 3 lots.
- Detection Limit: Samples with hCG spiked at concentrations of 0, 12.5, 16, 18.75, 20, 22.5, 25, 27.5, 50 and 100mIU/mL in urine, each concentration detected 90 times totally in each test site.
- Cross-reactivity: 20 fresh urine specimens for each homologous hormone.
- Interference: Not explicitly specified, "Three devices of each format were tested."
- Method Comparison: 360 fresh women urine samples.
- Lay-user Study: 120 female volunteers.
AUC: Not Found
MRMC: Not Found
Standalone performance:
- Precision/Reproducibility: All test results of samples with HCG concentration higher than 25 mIU/mL are positive (100% within 150 repeats for 25, 27.5, 100 mIU/mL). 98% of test results of samples with HCG concentration lower than 20 mIU/mL are negative. Good repeatability between lots and within lot.
- Detection Limit: Minimum detection limit is HCG 25 mIU/mL (positive ratio >95% for samples > 25 mIU/mL HCG). About 50% of test results for 22.5 mIU/mL HCG are positive.
- Analytical Specificity (Cross-reactivity): No cross reaction with LH at 500mIU/ml, FSH at 1000 mIU/mL, and TSH at 1000μIU/mL.
- Interference: No interference observed from listed compounds at specified concentrations.
- Effects of urine pH: pH ranging from 3 to 10 in urine samples does not interfere.
- Specific Gravity: Specific gravity ranging from 1.000 to 1.050 in urine samples does not interfere.
- High dose hook effect: No hook effect up to 2,000,000 mIU/mL hCG.
- Effects of hCG ß-core fragment: No hook effect observed at an hCG ß-core fragment concentration up to 100,000 pmol/L.
Key results:
- Method Comparison with predicate device: Total agreement rate with the predicate device was 100% for both professional use of the David Professional Pregnancy Test Cassette and David Home Pregnancy Test Cassette, and for lay-user testing vs. professional results with David Home Pregnancy Test Cassette.
- Lay-user study: All test results of samples containing 27.5mIU/mL of HCG are positive. 99% of test results of samples containing 20mIU/mL of HCG are negative. Lay-users found the test to be easy to use and had no trouble understanding labeling or interpreting results. Labels are understandable by people with no more than 8th grade education (Flesch-Kincaid software).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Precision/Reproducibility:
- HCG 25mIU/mL, 27.5mIU/mL, 100mIU/mL: 100% positive in tested samples across 3 lots (150/150).
- HCG 0mIU/mL, 16mIU/mL: 100% negative in tested samples across 3 lots (150/150).
- HCG 18.75mIU/mL: 1 positive out of 150 for each lot.
- HCG 20mIU/mL: 5/150, 3/150, 2/150 positive for each lot respectively (
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services and the Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
March 28, 2018
Runbio BioTech Co.,Ltd Chandler Chen OA Manager Rongsheng Technology Garden, Shantou University Road Shantou, Guangdong 515063, China
Re: K172627
Trade/Device Name: David Home Pregnancy Test Cassette David Professional Pregnancy Test Cassette Regulation Number: 21 CFR 862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX, JHI Dated: February 9, 2018 Received: February 12, 2018
Dear Chandler Chen:
We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976. the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerelv.
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K172627
Device Name David Home Pregnancy Test Cassette
Indications for Use (Describe)
David Home Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for the Over-the-Counter Use only.
| Type of Use (Select one or both, as applicable) |
|---|
| Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
|X | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Indications for Use
510(k) Number (if known) K172627
Device Name
David Professional Pregnancy Test Cassette
Indications for Use (Describe)
David Professional Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for prescription use only.
| Type of Use (Select one or both, as applicable) |
|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(k) SUMMARY
This summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.
The Assigned 510(k) number is K172627. DATE of Summary: March 01, 2018
A. Applicant Information
-
- Company Name: RUNBIO BIOTECH CO.,LTD
-
- Address: RONGSHENG TECHNOLOGICAL ZONE, UNIVERSITY ROAD
SHANTOU, GUANGDONG,CHINA 515063
-
- Telephone No.: 86-754-82528311
-
- Fax: 86-754-82537111
B. Contact Information
-
- Contact Person : Chandler Chen
-
- Company Name: RUNBIO BIOTECH CO.,LTD
-
- Address: RONGSHENG TECHNOLOGICAL ZONE, UNIVERSITY ROAD
SHANTOU , GUANGDONG,CHINA 515063
-
- Telephone No.: 86-754-82537812
- 5.Fax No.: 86-754-82537111
- 6.E-mail Address:runiroad@126.com
Proprietary and Established Names ﻥ
David Home Pregnancy Test Cassette
David Professional Pregnancy Test Cassette
D.Regulatory Information
1.Regulation section:
21 CFR 862.1155 Human Chorionic Gonadotropin (HCG) test system
2.Classification:
5
Class II
3.Product Code:
LCX, kit, test, pregnancy, hCG, over the counter JHI, visual, pregnancy hCG, prescription use
4. Classification Panel:
Clinical Chemistry (75)
Intended Use/Indication(s) for use Indications for use:
David Home Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for the Over-the-Counter Use only.
David Professional Pregnancy Test Cassette is an in-vitro diagnostic test for the qualitative determination of human chorionic gonadotropin (HCG) in the urine to aid in early detection of pregnancy, based on lateral flow immunoassay. It is intended for prescription use only.
2.Special conditions for use statement(s):
David Home Pregnancy Test Cassette is for the Over-the-Counter only. David Professional Pregnancy Test Cassette is for the prescription use only.
E.Device Description:
David Pregnancy Test Cassette will be designed in one format:Cassette.The Cassette kit consists of one test device, a disposable plastic dropper, and a package insert. Each test strip contains mouse monoclonal anti-a-hCG antibody coated
6
membrane and a pad containing mouse monoclonal anti-ß-hCG antibody colloidal gold conjugate. The control antibodies are goat anti-mouse IgG polyclonal antibody.
F. Substantial Equivalence Information
1.Predicate Device Name(s):
Wondfo One Step HCG Urine Pregnancy Test
2.Predicate 510(K)Number(s):
3.Comparison with predicate
| Similarities and Differences | ||
|---|---|---|
| Item | Predicate device | Candidate device |
| Device | Wondfo One Step HCG Urine Pregnancy Test | David Home Pregnancy Test |
| David Professional Pregnancy Test | ||
| Format | Strip,Cassette and midstream | Cassette |
| Cassette | ||
| Intended Use | Qualitative detection of Human Chorionic Gonadotrophine ( hCG ) in urine to aid in the detection of pregnancy hormone | Same |
| Same | ||
| Test Principle | Sandwich Immunochromatographic Assay | Same |
| Same | ||
| Methodology | Colloidal Gold Immunoassay (Membrane particle assay) | same |
| same | ||
| Test Line | Mouse monoclonal anti-α hCG antibodies | Same |
| Same | ||
| Detection Antibody | Mouse monoclonal anti-β hCG antibodies | Same |
| Same | ||
| Intended User | Prescription use (strip and cassette) and OTC use (strip, cassette and midstream) | OTC use (cassette ) |
| Prescription use (cassette) | ||
| Device format | strip, cassette and midstream | cassette |
| cassette | ||
| Sample Matrix | Human urine | same |
| same | ||
| Target Population | Pregnant women | Same |
| Same | ||
| Sterility | Non-sterile | Same |
| Same | ||
| Sensitivity | 25mIU/mL | Same |
| Same | ||
| Specificity | LH at 300 mIU/mL, FSH at 300 mIU/mL, and TSH at 1000 mIU/mL | LH at 500 mIU/mL, FSH at 1000 mIU/mL, and TSH at 1000 μIU/mL |
| LH at 500 mIU/mL, FSH at 1000 mIU/mL, and TSH at 1000 μIU/mL | ||
| pH Interference | No interference for urine with pH 4-9 | No interference for urine with pH 3-10 |
| No interference for urine with pH 3-10 | ||
| Specific Gravity Interference | No interference for urine with Specific Gravity 1.000-1.050 | Same |
| Same |
7
| High
Dosage
Hook effect | No high dosage hook effect for hCG up
to 100,000 mIU/mL | No high dosage hook effect for
hCG up to
2000,000 mIU/mL | No high dosage hook effect for
hCG up to
2000,000 mIU/mL |
|-------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Storage
Temperature | 4 to 30°C | 2 to 30 °C | 2 to 30 °C |
| Read time | 3 to 5 Minutes | 5 to 15 Minutes | 5 to 15 Minutes |
| Traceability | WHO 3rd International Standard | WHO
International
Standard 5th WHO
Chorionic
Gonadotrophin
( NIBSC code:
07/364) | WHO
International
Standard 5th WHO
Chorionic
Gonadotrophin
( NIBSC code:
07/364) |
G. Test Principle:
a qualitative, solid phase, double antibodies sandwich The test is immunochromatographic assay. Each test device contains mouse monoclonal anti-ßhCG antibody colloidal gold conjugate pre-dried on a pad. Mouse monoclonal antiα-hCG antibody (on the Test Line) and goat anti-mouse IgG polyclonal antibody (on the Control Line) are coated and immobilized on a nitrocellulose membrane.
For the cassette device, the sample is pipette onto the sample well.
During the test, hCG in the urine specimen reacts with the dye conjugate (mouse anti-ß-hCG antibody- colloidal gold conjugate specific to the beta subunit of hCG) and forms a complex. The complex migrates along the membrane to the mouse anti-α-hCG antibody test region (T), and remains captured in the T line.
J. Performance Characteristics:
1. Analytical performance
a. Precision/Reproducibility
8
The study was conducted in three (3) sites by a total of 9 operators with 3 lots of proposed device over 5 non-consecutive days. The samples were used with hCG spiked at the concentrations of 0, 16, 18.75, 20, 25, 27.5 and 100mIU/mL in urine. The result demonstrated that all the test results of samples with the HCG concentration higher than 25 mIU/mL are positive, and 98% of the test results of samples with the HCG concentration lower than 20 mIU/mL are negative. The colour of test line should keep consistant for each concentration sample.
According to the consistency of test results of the same sample, it can also be determined that the reagent has good repeatability between lots and within lot.
| Test Concentration | Lot No.: 1 | Lot No.:2 | Lot No.:3 | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| HCG0mIU/mL | +/+(0/150) | -/-(150/150) | +/+(0/150) | -/-(150/150) | +/+(0/150) | -/-(150/150) |
| HCG16mIU/mL | +/+(0/150) | -/-(150/150) | +/+(0/150) | -/-(150/150) | +/+(0/150) | -/-(150/150) |
| HCG18.75mIU/mL | +/+(1/150) | -/-(149/150) | +/+(1/150) | -/-(149/150) | +/+(1/150) | -/-(149/150) |
| HCG 20mIU/mL | +/+(5/150) | -/-(145/150) | +/+(3/150) | -/-(147/150) | +/+(2/150) | -/-(148/150) |
| HCG 25mIU/mL | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) |
| HCG 27.5mIU/mL | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) |
| HCG 100mIU/mL | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) | +/+(150/150) | -/-(0/150) |
Statistical table of repeatability test results of different lots
b. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
The test is calibrated against the WHO International Standard 5th WHO Chorionic Gonadotrophin ( NIBSC code: 07/364 )
Stability:
The applicant claims a 24-month shelf life for the test when stored at 36-86 F (2-30 ℃).
Expected values :
-
- Negative results are expected in healthy non-pregnant women
- The amount of hCG will vary greatly with gestational age and between individuals.
- c. Detection limit:
9
The study was conducted in three (3) sites by a total of 3 operators and by 30 volunteers with 3 lots of proposed device over 5 non-consecutive days. The samples were used with hCG spiked at the concentrations of 0, 12.5, 16, 18.75, 20, 22.5, 25, 27.5, 50 and 100mIU/mL in urine.
Each concentration was detected for 90 times totally in each test sites, 60 times by professionals using professional test kit and Home use test kit for either 30 times respectively, and 30 times by lay users in total. The comprehensive test result statistics demonstrated that the positive ratio of samples containing more than 25 mIU/mL HCG are more than 95%, so the minimum detection limit of the reagent is HCG 25 mIU/mL; about 50% of the test results of samples containing 22.5 mIU/mL HCG are positive.
| Professional User | Lay User | |||||
|---|---|---|---|---|---|---|
| Test Concentration | David Professional | |||||
| Pregnancy Test | ||||||
| Cassette | David Home Pregnancy Test | |||||
| Cassette | David Home Pregnancy | |||||
| Test Cassette | ||||||
| Positive | Positive | |||||
| Ratio | Positive | Positive | ||||
| Ratio | Positive | Positive | ||||
| Ratio | ||||||
| HCG0mIU/mL | +/+(0/90) | 0% | +/+(0/90) | 0% | +/+(0/90) | 0% |
| HCG 12.5mIU/mL | +/+(0/90) | 0% | +/+(0/90) | 0% | +/+(0/90) | 0% |
| HCG 16mIU/mL | +/+(0/90) | 0% | +/+(0/90) | 0% | +/+(0/90) | 0% |
| HCG 18.75mIU/mL | +/+(1/90) | 1.1% | +/+(2/90) | 2.2% | +/+(1/90) | 1.1% |
| HCG 20mIU/mL | +/+(6/90) | 6% | +/+(7/90) | 7% | +/+(3/90) | 6% |
| HCG 22.5mIU/mL | +/+(45/90) | 50% | +/+(51/90) | 56% | +/+(40/90) | 45% |
| HCG 25mIU/mL | +/+(90/90) | 100% | +/+(90/90) | 100% | +/+(90/90) | 100% |
| HCG 27.5mIU/mL | +/+(90/90) | 100% | +/+(90/90) | 100% | +/+(90/90) | 100% |
| HCG 50mIU/mL | +/+(90/90) | 100% | +/+(90/90) | 100% | +/+(90/90) | 100% |
| HCG 100mIU/mL | +/+(90/90) | 100% | +/+(90/90) | 100% | +/+(90/90) | 100% |
Table: Summary of Test Results
d. Analytical specificity:
Cross reactivity:
To evaluate cross-reactivity, 20 fresh urine specimens obtained from 10 healthy non-pregnant women and 10 healthy men were spiked with different
10
concentrations of Lutenizing Hormone (LH), Follicle stimulating Hormone (FSH), and thyroid stimulating hormone (TSH) into negative (0 mIU/mL) and positive (25mIU/ml) samples. The results demonstrated no cross reaction with LH at 500mIU/ml, FSH at 1000 mIU/mL, and TSH at 1000μIU/mL. Results are tabulated below.
| HCG
concentration | Homologous
hormone concentration | LOT NO. | | |
|----------------------|-------------------------------------|-------------|-------------|-------------|
| | | 20120901 | 20120902 | 20120903 |
| HCG 0mIU/mL | LH 500mIU/mL | -/- (20/20) | -/- (20/20) | -/- (20/20) |
| | FSH 1000mIU/mL | -/- (20/20) | -/- (20/20) | -/- (20/20) |
| | TSH 1000 $ \mu $ IU/mL | -/- (20/20) | -/- (20/20) | -/- (20/20) |
| HCG 25mIU/mL | LH 500mIU/mL | +/+ (20/20) | +/+ (20/20) | +/+ (20/20) |
| | FSH 1000mIU/mL | +/+ (20/20) | +/+ (20/20) | +/+ (20/20) |
| | TSH 1000 $ \mu $ IU/mL | +/+ (20/20) | +/+ (20/20) | +/+ (20/20) |
Table: test results of Specificity
Interference:
A study was conducted to evaluate interference of specific exogenous compounds. Negative and positive hCG urine samples (25 mIU/mL) were individually spiked with the substances listed in the table below. Three devices of each format were tested. No interference was observed from the compounds at the concentrations listed below.
| Table: Interfering Substance | ||
|---|---|---|
| -- | ------------------------------ | -- |
| Substance | Concentration | Substance | Concentration |
|---|---|---|---|
| Glucose | 2g/dL | Acetaminophen | 20 mg/dL |
| Albumin | 2g/dL | Atropine | 20 mg/dL |
| protein | 2g/dL | Aspirin | 20 mg/dL |
| Bilirubin | 2mg/dL | Ascorbic Acid | 20 mg/dL |
| Hemoglobin | 1mg/dL | Ampicillin | 20mg/dL |
| Vitamins C | 20 mg/dL | Salicyclic Acid | 20 mg/dL |
| Caffeine | 20 mg/dL | Phenothiazine | 20 mg/dL |
| Gentisate | 20 mg/dL | Thiophene | 20 mg/dL |
| Gentisic Acid | 20 mg/dL | Ephedrine | 20mg/dL |
| Tetracycline | 20mg/dL | Ethanol | 1% |
| Acetylsalicylic Acid | 20 mg/dL | Phenylpropanolamine | 20 mg/dL |
11
Effects of urine pH:
A study was conducted to evaluate the effect of pH. Negative and positive hCG urine samples (25 mIU/mL) were tested across a pH range of 3-10. The results demonstrate that pH ranging from 3 to 10 in urine samples does not interfere with the performance of the test.
Specific Gravity:
A study was performed to evaluate the effects of urine specific gravity on the device. The device was challenged with negative urine and positive urine with specific gravity from 1.000 to 1.050. The results demonstrate that specific gravity ranging from 1.000 to 1.050in urine samples does not interfere with the performance of the test.
High dose hook effect study:
The test was evaluated for high dose hook effect. Negative urine specimens were spiked with high hCG concentration of of ranging from 50 mIU/mL to 2000,000 mIU/mL.All samples yielded the expected positive results. This study demonstrates that this device shows no hook effect up to 2,000,000 mIU/mL hCG.
Effects of hCG ß-core fragment:
Interference testing was performed to evaluate whether high levels of beta core fragment interfere with the device. Negative urine hCG (containing 0 mIU/mL hCG,16mIU/mL HCG) and positive urine samples (containing 27.5 mIU/mL hCG) were spiked with hCG beta core fragment standard (traceable to WHO reference reagent 99/708) at several different concentrations up to 1,000,000 pmol/L. The samples were tested using 3 different lots. Samples of each concentration were tested 10 times with the professional and lay-user respectively. However, the results demonstrated that no hook effect was observed at an hCG ß-core fragment concentration up to 100,000 pmol/L.
2. Comparison Study:
a. Method comparison with predicate device:
Totally 360 fresh women urine samples were tested at 3 sites. According to synchronous test results by the predicate device and candidate device by professionals, there were153 positive samples and 207 negative samples and all the test
12
results were the same as expected. The test results obtained by the lay-users and by the professionals with predicate device were exactly the same, which means the total agreement rate was 100%.
All lay users tested their own urine by themselves with David Home Pregnancy Test Cassette according to the instructions for use in English.
Table: statistic analysis of data (professionals)
| Predicate Device | ||||
|---|---|---|---|---|
| Wondfo One Step HCG Urine Test | ||||
| Positive | Negative | total | ||
| Proposed Device | ||||
| David Professional | ||||
| Pregnancy Test Cassette | Positive | (a)153 | (b)0 | (a+b)153 |
| Negative | (c)0 | (d)207 | (c+d)207 | |
| total | (a+c)153 | (b+d)207 | (a+b+c+d)360 |
Positive coincidence rate=[a/(a+c)]×100%=[153/(153+0)]×100%=100%;
Negative coincidence rate=[d(b+d)]×100%=[207/(207+0)]×100%=100%;
Totalcoincidencerate=[(a+d)/(a+b+c+d)]×100%=[(153+207)/(360)]×100%=100%.
| | | Predicate Device
Wondfo One Step HCG Urine Test | | |
|----------------------------------------------------------|----------|----------------------------------------------------|------------|----------------|
| | | Positive | Negative | total |
| Proposed Device
David Home Pregnancy
Test Cassette | Positive | (a)153 | (b)0 | $(a+b)153$ |
| | Negative | (c)0 | (d)207 | $(c+d)207$ |
| | total | $(a+c)153$ | $(b+d)207$ | $(a+b+c+d)360$ |
Table: statistic analysis of data (professionals)
Positive coincidence rate=[a((a+c)] x100%=[153/(153+0)]×100%=100% ;
Negative coincidence rate=[d/(b+d)]×100%=[207/(207+0)]×100%=100% ;
Totalcoincidencerate=[(a+d)/(a+b+c+d)]×100%=[(153+207)/(360)]×100%=100%.
Table: statistic analysis of data (David Home Pregnancy Test Cassette)
| Results of Professionals | ||||
|---|---|---|---|---|
| Positive | Negative | total | ||
| Results of | ||||
| non-Professionals | Positive | (a)153 | (b)0 | (a+b)153 |
| Negative | (c)0 | (d)207 | (c+d)207 | |
| total | (a+c)153 | (b+d)207 | (a+b+c+d)360 |
13
Positive coincidence rate=[a/(a+c)]×100%=[153/(153+0)]×100%=100%; Negative coincidence rate=[d/(b+d)] ×100%=[207/(207+0)]×100%=100% Total coincidence rate=[(a+d)(a+b+c+d)]×100%=[(153+207)/(360)]×100%=100%.
b.Lay-user study:
After finishing the comparison study, 40 female volunteers aged from 18-45 and of different occupation and education were selected from each of the three sites, for a total of 120 volunteers to participate in the lay-user study and and fill-out questionnaires to evaluate the users comprehension of the instructions for use. Lay users conducted the test according to the English instructions for use for the David Home Pregnancy Test Cassette without any assistance. After finishing the test on their own samples, all the 120 volunteers were asked to test 3 other samples spiked with HCG different of HCG27.5mIU/mL). Every volunteer randomly selected one set of double-blind numbered samples to test. The results showed that all the test results of samples containing 27.5mIU/mL of HCG are positive and 99% of the test results of samples containing 20mIU/mL of HCG are negative.
Every lay-user participant was asked to answer the Likert scale style questions in the questionnaire after finishing the above test. The respondents specified their level of agreement or disagreement to a statement on a scale of 1 to 5,for example, 1-strongly disagree, 2-disagree, 3-neither agree or disagree, 4-agree, and 5-strongly agree. The results of the questionnaire reflected that the lay-users found the test to be easy to use and that they did not have trouble understanding the labeling or interpreting results. The Flesch-Kincaid software was used to assess the readability of the packaging labels for lay-user use and the results show that the labels can be understood by people with no more than 8th grade education.
M.CONCLUSION:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.